不可切除胰腺癌患者常因难以控制、持续且令人丧失能力的疼痛而感到沮丧。此疼痛必须积极处理，并建议以强效鸦片类药物作为主要治疗。然而，患者会出现鸦片类药物相关不良事件。EUS 引导的腹腔神经丛阻断术（CPN）及腹腔神经节阻断术（CGN）已显示对疼痛控制具有高效能。然而，最佳时机仍存在争议。
适应症：Pancreatic Cancer Non-resectable、Tumor Pancreas、Pain Cancer
入组条件
纳入标准
- Age \>= 18 years old
- Diagnosed to have inoperable pancreatic cancer
- Presence of tumor pain (centrally located, constant, with no other obvious cause) with a VAS \>= 3
- Karnofsky performance status \>= 60
- Planned for EUS examination and/or biopsy of the pancreatic tumor
排除标准
- Allergy to bupivacaine, or alcohol
- Potentially operable after neoadjuvant therapy
- Expected survival of less than 3 months
- Patient who is already on opioids for pain control
- Previous percutaneous or EUS-guided CGN/ CPN
- Recurrent pancreatic tumors after operation
- Uncorrectable coagulopathy
- Inability or unwillingness to provide informed consent
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。